Analyst Upgrades Q1 EPS Forecast for Anavex Life Sciences

On December 26, 2024, investment analysts at HC Wainwright raised their earnings per share (EPS) forecasts for Anavex Life Sciences Corp. (NASDAQ:AVXL) regarding the first quarter of 2025. The analyst, R. Selvaraju, now predicts that the biotechnology firm will achieve a loss of ($0.17) per share for Q1 2025, an improvement from their earlier estimate of ($0.19) per share. HC Wainwright maintains a "Buy" rating on the company’s stock with a price target of $42.00. In addition, the consensus estimate for Anavex Life Sciences’ full-year earnings stands at a loss of ($0.55) per share. Further forecasts from HC Wainwright include a Q2 2025 EPS of ($0.18), a Q3 2025 EPS of ($0.21), and a full-year EPS of ($0.73) for FY2025.

In a separate report released on December 23, D. Boral Capital reaffirmed a "Buy" rating for Anavex Life Sciences and set a higher price target of $46.00 for its shares.

Current Stock Performance of Anavex Life Sciences

As of December 30, Anavex's stock opened at $12.11. The company boasts a market capitalization of approximately $1.03 billion, with a price-to-earnings ratio of -24.22. The stock's beta is recorded at 0.73. Anavex Life Sciences has recently seen its stock price fluctuate, with a 50-day moving average price of $8.29 and a 200-day moving average of $6.44. Over the past year, the stock reached a low of $3.25 and a high of $14.44.

In its latest earnings release on December 23, Anavex Life Sciences reported an EPS of ($0.14) for the previous quarter, surpassing the consensus estimate of ($0.17) by $0.03.

Institutional Investments in Anavex Life Sciences

Recent activities by institutional investors reflect changing sentiments toward Anavex Life Sciences. The Bank of New York Mellon Corp increased its stake in the company by 17.1% during the second quarter, owning 280,556 shares valued at $1,184,000 after adding 40,895 shares. Rhumbline Advisers also raised its stake by 15.8%, currently holding 119,289 shares worth $503,000 after acquiring an additional 16,293 shares. Furthermore, Renaissance Technologies LLC dramatically increased its presence in Anavex Life Sciences by 483.8%, owning 466,437 shares valued at $1,968,000 after adding 386,537 shares during the same quarter. New stakes were also acquired by Marshall Wace LLP at approximately $166,000, and Squarepoint Ops LLC, which invested about $191,000. Collectively, institutional investors own around 31.55% of Anavex Life Sciences’ outstanding shares.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. operates as a clinical stage biopharmaceutical firm focused on developing therapeutics for central nervous system diseases. The company’s flagship product candidate is ANAVEX 2-73, aimed at treating Alzheimer's disease, Parkinson's disease, and various other central nervous system conditions, including rare disorders such as Rett syndrome, infantile spasms, Fragile X syndrome, and Angelman syndrome.

Analyst, Forecast, Anavex